On February 22, 2017, Ma, Xiaodong; Yu, Haiqing; Song, Anran; Ge, Yang; Song, Zhendong; Huang, Shanshan; Wang, Changyuan; Liu, Kexin published a patent.SDS of cas: 16230-24-3 The title of the patent was Preparation of purine compounds as BTK tyrosine kinase inhibitors for treating large B cell lymphoma, follicular lymphoma or chronic lymphocytic leukemia. And the patent contained the following:
The invention relates to purine compounds, isomers or pharmaceutically acceptable salts or hydrates with formula of I, wherein R1 is one of H, methoxy, Me, chloro or fluoro; R2 is morpholine, 1-methylpiperazine, 1-ethylpiperazine, etc. The invention compounds can be used for treating diseases caused by BTK tyrosine kinase, especially disseminated anaplastic large B cell lymphoma, follicular lymphoma or chronic lymphocytic leukemia. The experimental process involved the reaction of N-(3-Aminophenyl)acrylamide(cas: 16230-24-3).SDS of cas: 16230-24-3
The Article related to purine preparation btk tyrosine kinase inhibitor lymphoma leukemia, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.SDS of cas: 16230-24-3
Referemce:
Amide – Wikipedia,
Amide – an overview | ScienceDirect Topics